Graham K.  Cooper net worth and biography

Graham Cooper Biography and Net Worth

Director of Beam Therapeutics

Graham Cooper is a member of the boards of directors of other public companies including Unity Biotechnology and Kezar Life Sciences.

Mr. Cooper is focused on financial operations and capital markets strategy. He was previously the chief financial officer and chief operating officer of Assembly Biosciences, a biotechnology company developing therapeutics targeting hepatitis B virus. Prior to joining Assembly, he was chief financial officer of Receptos, from 2013 until its sale in 2015 to Celgene.

Previously, Mr. Cooper was the chief financial officer of Geron Corporation, and from 2006 until 2011, served as chief financial officer of Orexigen Therapeutics. From 1999 to 2006, Mr. Cooper held positions of increasing responsibility including director of healthcare investment banking at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From 1992 to 1995, he worked as an accountant at Deloitte & Touche, where he earned his C.P.A. (currently inactive).

Mr. Cooper holds a B.A. in economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.

What is Graham K. Cooper's net worth?

The estimated net worth of Graham K. Cooper is at least $317,988.00 as of June 28th, 2021. Mr. Cooper owns 12,045 shares of Beam Therapeutics stock worth more than $317,988 as of December 10th. This net worth evaluation does not reflect any other assets that Mr. Cooper may own. Learn More about Graham K. Cooper's net worth.

How do I contact Graham K. Cooper?

The corporate mailing address for Mr. Cooper and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected]. Learn More on Graham K. Cooper's contact information.

Has Graham K. Cooper been buying or selling shares of Beam Therapeutics?

Graham K. Cooper has not been actively trading shares of Beam Therapeutics during the last ninety days. Most recently, Graham K. Cooper sold 2,614 shares of the business's stock in a transaction on Tuesday, July 6th. The shares were sold at an average price of $120.61, for a transaction totalling $315,274.54. Learn More on Graham K. Cooper's trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 12 times. They sold a total of 284,412 shares worth more than $10,417,585.03. The most recent insider tranaction occured on October, 30th when insider Amy Simon sold 3,448 shares worth more than $64,477.60. Insiders at Beam Therapeutics own 4.4% of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 10/30/2023.

Graham K. Cooper Insider Trading History at Beam Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/6/2021Sell2,614$120.61$315,274.54View SEC Filing Icon  
6/28/2021Sell12,045$106.34$1,280,865.3012,045View SEC Filing Icon  
See Full Table

Graham K. Cooper Buying and Selling Activity at Beam Therapeutics

This chart shows Graham K Cooper's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $26.40
Low: $26.29
High: $28.79

50 Day Range

MA: $23.95
Low: $17.69
High: $30.76

2 Week Range

Now: $26.40
Low: $16.95
High: $51.60


1,780,125 shs

Average Volume

1,444,542 shs

Market Capitalization

$2.15 billion

P/E Ratio


Dividend Yield